B-Cell Depletion by Anti-CD20 (Rituximab) in Renal Allograft Recipients Who Develop De Novo Anti-HLA Alloantibodies will Result in Inhibition of Alloantibody Production and Attenuation of Chronic Humoral Rejection (CTOT-02/CCTPT-02)

Grant

Date/time Interval

  • September 1, 2007 - August 31, 2012
  • Total Award Amount

  • 260250.00
  • Direct Costs

  • 191897.00
  • Sponsor Award Id

  • Contributor

  • Vineeta Kumar   Principal Investigator